Boston (Vocus) September 24, 2008 -- Neuroscientists at Children’s Hospital Boston have identified the first known “master switch” in brain cells to orchestrate the formation and maintenance of inhibitory synapses, essential for proper brain function. The factor, called Npas4, regulates more than 200 genes that act in various ways to calm down over-excited cells, restoring a balance that is thought to go askew in some neurologic disorders. The findings appear in the September 24 advance online edition of the journal Nature.

Synapses, the connections between brain cells, can be excitatory or inhibitory in nature. At birth, the rapidly developing brain teems with excitatory synapses, which tend to make nerve cells “fire” and stimulate their neighbors. But if the excitation isn’t eventually balanced, it can lead to epilepsy, and diseases like autism and schizophrenia have been associated with an imbalance of excitation and inhibition. The creation of inhibitory connections is also necessary to launch critical periods -- windows of rapid learning during early childhood and adolescence, when the brain is very “plastic” and able to rewire itself.

Npas4 is a transcription factor, a switch that activates or represses other genes. The researchers, led by Michael Greenberg, PhD, director of the Neurobiology Program at Children’s, demonstrated that the activity of as many as 270 genes changes when Npas4 activity is blocked in a cell, and that Npas4 activation is associated with an increased number of inhibitory synapses on the cell’s surface.

The team further showed that Npas4 is activated by excitatory synaptic activity. "Excitation turns on a program that says, ‘this cell is getting excited, we need to balance that with inhibition,’” explains Greenberg, who now also chairs the Department of Neurobiology at Harvard Medical School.

Finally, the researchers bred live mice that lacked Npas4, and found evidence of neurologic problems – the mice appeared anxious and hyperactive and were prone to seizures.

Greenberg and colleagues are now trying to learn more about the wide variety of genes that Npas4 regulates, each of which could give clues to synapse development and reveal new treatment possibilities for neurologic disorders. “If you have your hand on a transcription factor such as Npas4, new genome-wide technology allows you to essentially identify every target of the transcription factor,” says Greenberg. One such target is neurotrophic factor (BDNF), which Greenberg and colleagues previously showed to regulate the maturation and function of inhibitory synapses.

Children’s researchers Takao Hensch, PhD, and Michela Fagiolini, PhD, also in the Neurobiology program, plan to study the Npas4-lacking mice to see if they have abnormalities in the initiation of critical periods; colleague Chinfei Chen, MD, PhD, will also study the mice, further probing how their synapses develop.

The study was supported by the F.M. Kirby Foundation, the Nancy Lurie Marks Family Foundation, the Lefler Foundation and the National Institutes of Health. Yingxi Lin, PhD, was first author.

Citation: Lin Y; et al. Activity-dependent regulation of GABAergic synapse development by Npas4. Nature Sep 24, 2008 [advance online publication.

After posting online, the article can be viewed at http://dx.doi.org/10.1038/nature07319.

Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 500 scientists, including eight members of the National Academy of Sciences, 11 members of the Institute of Medicine and 12 members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 397-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital and its research visit: www.childrenshospital.org/newsroom.

CONTACT: James Newton

Children’s Hospital Boston

617-919-3110

james.newton(at)childrens.harvard.edu

###

Simillar Articles

Curemark CEO Presents Autism Findings at Prestigious Neurobiology Conference at Oxford

Curemark, LLC announced today that Founder and CEO Dr. Joan Fallon has presented Curemark's most recent findings on autism at the Gordon Conference on Neurobiology and Brain Disorders which...

Study Reveals White Matter Changes in Schizophrenia

People recently diagnosed with schizophrenia have abnormalities in a specific area of the brain’s white matter. The study, published this month in the journal Neuropsychopharmacology,...

UBC's Dr. Wada, Internationally Acclaimed Researcher, Receives National Honours

The Canadian League Against Epilepsy, the national medical organization representing Canada internationally, will give Dr. Juhn Wada, former University of British Columbia (UBC) epilepsy...

Mom Teams With Specialist to Spread Awareness of Innovative Treatment Options for Epilepsy and...

On June 4, Arlene Martell and Dr. Paul Swingle will take part in a free teleseminar discussion of the newest alternative treatments for autism, epilepsy, and other brain disorders, with a focus on...

Cleveland Clinic Press Consumer Health Book Empowers and Gives Hope to People with Epilepsy

"Epilepsy: A Cleveland Clinic Guide" by Elaine Wyllie, M.D. is an enlightening consumer health book that demystifies epilepsy and empowers patients to help control their seizures and their lives.

Home